|Primary Industry:||Health & Medical Devices|
|Executive Summary:||Anergix, LLC is developing a combined cell/gene therapy treatment for multiple sclerosis (MS), a disease that affects roughly 400,000 Americans and 2.5 million worldwide. The therapeutic strategy is to induce immune tolerance to one or more of the suspected antigens thought to cause the autoimmune response against the myelin sheath proteins surrounding nerve cells. Tolerance, or anergy, is a state of diminished immune response to a particular antigen.
The value of the Anergix technology rests upon several important factors: (1) antigen specificity by using MBP or PLP peptides will not lead to the broader immunomodulatory effects seen by current Disease Modifying Therapies; (2) subcutaneous implants will eliminate the need for frequent im, sc or iv injections; (3) together, these first two advantages will mean fewer side-effects and better long term compliance on the part of MS patients. One aim of our clinical research program will be to establish efficacy of a single annual implant. If successful, the Anergix approach will benefit all MS patients, particularly those in rural settings (~30%) that are not treated today because of lack of access to comprehensive MS treatment centers comprising neurologists, nurses, social workers, and psychologists.